A gp130-Src-YAP module links inflammation to epithelial regeneration

Nature

Volumn 519, Issue 7541, 2015, Pages 57-62

  Taniguchi, Koji ^a,b,c   Wu, Li Wha ^a,d   Grivennikov, Sergei I ^a,e   De Jong, Petrus R ^f   Lian, Ian ^a,g,h   Yu, Fa Xing ^a,g,i   Wang, Kepeng ^a   Ho, Samuel B ^j   Boland, Brigid S ^f   Chang, John T ^f   Sandborn, William J ^f   Hardiman, Gary ^k,l   Raz, Eyal ^f   Maehara, Yoshihiko ^b   Yoshimura, Akihiko ^c,m   Zucman Rossi, Jessica ^n,o   Guan, Kun Liang ^a,g   Karin, Michael ^a,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KYUSHU UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e FOX CHASE CANCER CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h LAMAR UNIVERSITY   (United States)

ⁱ FUDAN UNIVERSITY   (China)

^j VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^l SAN DIEGO STATE UNIVERSITY   (United States)

^m JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

ⁿ INSERM   (France)

^o San Diego   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; DIBENZAZEPINE DERIVATIVE; GLYCOPROTEIN GP 130; INTERLEUKIN 11; INTERLEUKIN 6; NOTCH RECEPTOR; PROTEIN KINASE YES; PROTEIN S6; PROTEIN TYROSINE KINASE; PROTEIN YAP; REGULATOR PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR HES 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VILLIN; PHOSPHOPROTEIN; PROTEIN KINASE P60; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP PROTEIN, MOUSE;

CANCER; GENE EXPRESSION; PROTEIN; REGROWTH; RODENT; SIGNALING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; EPITHELIUM CELL; GENE EXPRESSION; HOMEOSTASIS; HUMAN; HUMAN CELL; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TISSUE GROWTH; TISSUE INJURY; TISSUE REGENERATION; ANIMAL; BODY WEIGHT; CYTOLOGY; DISEASE MODEL; ENZYME ACTIVATION; HEK293 CELL LINE; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; REGENERATION; SIGNAL TRANSDUCTION; UPREGULATION;

MUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BODY WEIGHT; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE RECEPTOR GP130; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; EPITHELIAL CELLS; HEK293 CELLS; HOMEOSTASIS; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICE; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-YES; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTORS, NOTCH; REGENERATION; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84924328294     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14228     Document Type: Article

References (60)

1. Ben-Neriah, Y. & Karin, M. Inflammation meets cancer, with NF-kB as the matchmaker. Nature Immunol. 12, 715-723 (2011).
2. Medzhitov, R. Origin and physiological roles of inflammation. Nature 454, 428-435 (2008).
3. Baddour, J. A., Sousounis, K. & Tsonis, P. A. Organ repair and regeneration: an overview. Birth Defects Res. C 96, 1-29 (2012).
4. Johnson, R. & Halder, G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nature Rev. Drug Discov. 13, 63-79 (2014).
5. Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-899 (2010).
6. Neurath, M. F.Newtargets formucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 7, 6-19 (2014).
7. Garbers, C. et al. Plasticity and cross-Talk of interleukin 6-Type cytokines. Cytokine Growth Factor Rev. 23, 85-97 (2012).
8. Kishimoto, T. IL-6: from its discovery to clinical applications. Int. Immunol. 22, 347-352 (2010).
9. Yoshimura, A., Naka, T. & Kubo, M.SOCSproteins, cytokine signalling andimmune regulation. Nature Rev. Immunol. 7, 454-465 (2007).
10. Putoczki, T. & Ernst, M. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J. Leukoc. Biol. 88, 1109-1117 (2010).
11. Rose-John, S., Mitsuyama, K., Matsumoto, S., Thaiss, W. M. & Scheller, J. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Curr. Pharm. Des. 15, 2095-2103 (2009).
12. Pilati, C. et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J. Exp. Med. 208, 1359-1366 (2011).
13. Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-Associated cancer. Cancer Cell 15, 103-113 (2009).
14. Rebouissou, S. et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457, 200-204 (2009).
15. Tanaka, T., Narazaki, M. & Kishimoto, T. Therapeutic targeting of the interleukin-6 receptor. Annu. Rev. Pharmacol. Toxicol. 52, 199-219 (2012).
16. Cai, J. et al. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 24, 2383-2388 (2010).
17. Okamoto, R. et al. Requirement of Notch activation during regeneration of the intestinal epithelia. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G23-G35 (2009).
18. Yu, F. X. & Guan, K. L. The Hippo pathway: regulators and regulations. Genes Dev. 27, 355-371 (2013).
19. Rosenbluh, J. et al. b-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457-1473 (2012).
20. Bray, S. J. Notch signalling: a simple pathway becomes complex. Nature Rev. Mol. Cell Biol. 7, 678-689 (2006).
21. Madison, B. B. et al. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J. Biol. Chem. 277, 33275-33283 (2002).
22. Camargo, F. D. et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr. Biol. 17, 2054-2060 (2007).
23. Zhou, D. et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-Associated protein (Yap) overabundance. Proc. Natl Acad. Sci. USA 108, E1312-E1320 (2011).
24. Fre, S. et al. Notch signals control the fate of immature progenitor cells in the intestine. Nature 435, 964-968 (2005).
25. van Es, J. H. et al. Notch/c-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959-963 (2005).
26. Sato, T. & Clevers, H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 340, 1190-1194 (2013).
27. Sato, T. et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469, 415-418 (2011).
28. Murakami, D. et al. Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. Oncogene 22, 1511-1516 (2003).
29. Zhang, J. et al. YAP-dependent induction of amphiregulin identifies a non-cellautonomous component of the Hippo pathway. Nature Cell Biol. 11, 1444-1450 10.1038/ncb1993 (2009).
30. Nishioka, N. et al. The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguishmouse trophectodermfrominner cell mass. Dev. Cell 16, 398-410 (2009).
31. Chen, J., Elfiky, A., Han, M., Chen, C. & Saif, M. W. The role of Src in colon cancer and its therapeutic implications. Clin. Colorectal Cancer 13, 5-13 (2014).
32. Levy, D., Adamovich, Y., Reuven, N. & Shaul, Y. Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Mol. Cell 29, 350-361 (2008).
33. Azzolin, L. et al. YAP/TAZ incorporation in the b-catenin destruction complex orchestrates the Wnt response. Cell 158, 157-170 (2014).
34. Sudol, M. Yes-Associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 9, 2145-2152 (1994).
35. Tsutsumi, R. et al. YAP and TAZ, Hippo signaling targets, act as a rheostat for nuclear SHP2 function. Dev. Cell 26, 658-665 (2013).
36. Tschaharganeh, D. F. et al. Yes-Associated protein up-regulates Jagged-1 and activates theNotch pathway inhuman hepatocellular carcinoma.Gastroenterology 144, 1530-1542 (2013).
37. Li, Y., Hibbs, M. A., Gard, A. L., Shylo, N. A. & Yun, K. Genome-wide analysis of N1ICD/RBPJ targets in vivo reveals direct transcriptional regulation of Wnt, SHH, and hippo pathway effectors by Notch1. Stem Cells 30, 741-752 (2012).
38. Yu, F. X. et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150, 780-791 (2012).
39. Gordon, M. et al. The tumor suppressor gene, RASSF1A, is essential for protection against inflammation-induced injury. PLoS ONE 8, e75483 (2013).
40. Tamm, C., Bower, N. & Anneren, C. Regulation of mouse embryonic stem cell self-renewal by a Yes-YAP-TEAD2 signaling pathway downstreamof LIF. J. Cell Sci. 124, 1136-1144 (2011).
41. Raz, R., Lee, C. K., Cannizzaro, L. A., dEustachio, P. & Levy, D. E. Essential role of STAT3 for embryonic stem cell pluripotency. Proc. Natl Acad. Sci. USA 96, 2846-2851 (1999).
42. Taniguchi, K. & Karin, M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin. Immunol. 26, 54-74 (2014).
43. Hedvat, M. et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16, 487-497 (2009).
44. Cordero, J. B. et al. c-Src drives intestinal regeneration and transformation.EMBOJ. 33, 1474-1491 (2014).
45. Takeda, K. et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39-49 (1999).
46. Zhang, N. et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 19, 27-38 (2010).
47. Ootani, A. et al. Sustained in vitro intestinal epithelial culture within a Wntdependent stem cell niche. Nature Med. 15, 701-706 (2009).
48. Holzer, R. G. et al. Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation. Cell 147, 173-184 (2011).
49. Hu, H. T. et al. Tie2-R849W mutant in venous malformations chronically activates a functional STAT1 to modulate gene expression. J. Invest. Dermatol. 128, 2325-233310.1038/jid.2008.89 (2008).
50. Nam, J. S., Ino, Y., Sakamoto, M. & Hirohashi, S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin. Cancer Res. 8, 2430-2436 (2002).
51. Lee, S. H. et al. ERK activation drives intestinal tumorigenesis in Apcmin/1 mice. Nature Med. 16, 665-670 (2010).
52. Hu, L., Zaloudek, C., Mills, G. B., Gray, J. & Jaffe, R. B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res. 6, 880-886 (2000).
53. Katakura, K. et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 115, 695-702 (2005).
54. Sato, T. et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262-265 (2009).
55. Sato, T. et al. Long-Term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barretts epithelium. Gastroenterology 141, 1762-1772 (2011).
56. Guma, M. et al. Constitutive intestinal NF-kB does not trigger destructive inflammation unless accompanied by MAPK activation. J. Exp. Med. 208, 1889-1900 (2011).
57. Barker, N. et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003-1007 (2007).
58. Umemura, A. et al. Liver damage, inflammation, andenhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab. 20, 133-144 (2014).
59. Mitchell, C. & Willenbring, H. A reproducible and well-Tolerated method for 2/3 partial hepatectomy in mice. Nature Protocols 3, 1167-1170 (2008).
60. Kozak, I. et al. A degenerative retinal process in HIV-Associated non-infectious retinopathy. PLoS ONE 8, e74712 (2013).